2-benzyloxy-3-chlorophenol | 56207-40-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-benzyloxy-3-chlorophenol
• 英文别名: 3-Chloro-2-phenylmethoxyphenol
• CAS: 56207-40-0
• 化学式: C₁₃H₁₁ClO₂
• 分子量: 234.682
• InChiKey: PMMQGCGRTBLWHT-UHFFFAOYSA-N

物化性质

• 沸点：
  361.6±27.0 °C(Predicted)
• 密度：
  1.271±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-benzyloxy-3-chlorophenol 在 盐酸 、 palladium on activated charcoal 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 34.0h， 生成 (R)-2-mesyloxymethyl-8-chloro-1,4-benzodioxane
  参考文献：
  名称：

  Affinity and activity profiling of unichiral 8-substituted 1,4-benzodioxane analogues of WB4101 reveals a potent and selective α1B-adrenoceptor antagonist

  摘要：

  Unichiral 8-substituted analogues of 2-[(2-(2,6-dimethoxyphenoxy)ethyl)aminomethyl]-1,4-benzodioxane (WB4101) were synthesized and tested for binding affinity at cloned human alpha(1a), alpha(1b)-and alpha(1d)-adrenoreceptor (alpha(1a)-, alpha(1b)-and alpha(1d)-AR) and at native rat 5-HT1A receptor and for antagonist affinity at MIA". affrand am-AR and at a2A/D-AR. Among the selected 8-substituents, namely fluorine, chlorine, methoxyl and hydroxyl, only the last caused significant decrease of alpha(1) binding affinity in comparison with the lead compound. Functional tests on the S isomers confirmed the detrimental effect of OH positioned in proximity to benzodioxane O(1). For the other three substituents (F, Cl, OMe), the alp and the am antagonist affinities were generally lower than the alpha(1a) and alpha(1d) binding affinities, but not the alpha(1B) antagonist affinity, which was similar and sensibly higher compared to alpha(1b) binding affinity in the case of F and OMe respectively. This trend confers significant alpha(1B)-AR selectivity, in particular, to the 8-methoxy analogue of (S)-WB4101, a new potent (pA(2) 9.58) alpha(1B)-AR antagonist. The S enantiomers of all the tested compounds were proved to act as al-AR inverse agonists in a vascular model. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.09.049
• 作为产物：
  描述：

  2-氯苯基乙酸酯 在 aluminum (III) chloride 、 四丁基溴化铵 、 水 、 间氯过氧苯甲酸 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 、 邻二氯苯 为溶剂， 反应 180.0h， 生成 2-benzyloxy-3-chlorophenol
  参考文献：
  名称：

  Affinity and activity profiling of unichiral 8-substituted 1,4-benzodioxane analogues of WB4101 reveals a potent and selective α1B-adrenoceptor antagonist

  摘要：

  Unichiral 8-substituted analogues of 2-[(2-(2,6-dimethoxyphenoxy)ethyl)aminomethyl]-1,4-benzodioxane (WB4101) were synthesized and tested for binding affinity at cloned human alpha(1a), alpha(1b)-and alpha(1d)-adrenoreceptor (alpha(1a)-, alpha(1b)-and alpha(1d)-AR) and at native rat 5-HT1A receptor and for antagonist affinity at MIA". affrand am-AR and at a2A/D-AR. Among the selected 8-substituents, namely fluorine, chlorine, methoxyl and hydroxyl, only the last caused significant decrease of alpha(1) binding affinity in comparison with the lead compound. Functional tests on the S isomers confirmed the detrimental effect of OH positioned in proximity to benzodioxane O(1). For the other three substituents (F, Cl, OMe), the alp and the am antagonist affinities were generally lower than the alpha(1a) and alpha(1d) binding affinities, but not the alpha(1B) antagonist affinity, which was similar and sensibly higher compared to alpha(1b) binding affinity in the case of F and OMe respectively. This trend confers significant alpha(1B)-AR selectivity, in particular, to the 8-methoxy analogue of (S)-WB4101, a new potent (pA(2) 9.58) alpha(1B)-AR antagonist. The S enantiomers of all the tested compounds were proved to act as al-AR inverse agonists in a vascular model. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.09.049

文献信息

• [EN] BICYCLIC DERIVATIVES AS PPAR MODULATORS<br/>[FR] DERIVES BICYCLIQUES EN TANT QUE MODULATEURS DE PPAR
  申请人：LILLY CO ELI

  公开号：WO2005066136A1

  公开（公告）日：2005-07-21

  The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.

  本发明涉及由以下结构公式（I）表示的化合物，以及它们的立体异构体、药用可接受的盐、溶剂化物和水合物，其中：(a) R2 是由C0-C8烷基和C1-4-杂烷基组成的组中选出的；(b) X 是由单个键、O、S、S(O)2和N组成的组中选出的；(c) U 是一个脂肪族连接链，其中脂肪族连接链的一个碳原子可选地被O、NH或S替换，并且这样的脂肪族连接链可被选自R30的一个到四个取代基独立地取代；(d) Y 是由C、O、S、NH和单个键组成的组中选出的；以及(e) E 是C(R3)(R4)A或A。
• [EN] FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS<br/>[FR] DERIVES HETEROCYCLIQUES FUSIONNES UTILISES EN TANT QUE MODULATEURS PPAR
  申请人：LILLY CO ELI

  公开号：WO2004063155A1

  公开（公告）日：2004-07-29

  The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

  本发明涉及由以下结构式I表示的化合物：其中（a）X选自单键、O、S、S（O）2和N组成的群；（b）U是脂肪链连接物；（c）Y选自C、O、S、NH和单键组成的群；（d）E是C（R3）（R4）A或A，其中（i）A选自羧基、四唑基、C1-C6烷基腈、羧酰胺、磺酰胺和酰基磺酰胺组成的群；（e）B选自S、O、C和N组成的群；（f）Z选自N和C组成的群；但当B为C时，则Z为N。
• [EN] PPAR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR)
  申请人：LILLY CO ELI

  公开号：WO2005019151A1

  公开（公告）日：2005-03-03

  The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种具有式I的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物在治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中具有用途，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉硬化以及与X综合征和心血管疾病相关的其他疾病。
• Ppar modulators
  申请人：Gonzalez Valcarcel Isabel Cristina

  公开号：US20060257987A1

  公开（公告）日：2006-11-16

  The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种化合物I，或其药学上可接受的盐、溶剂化物、水合物或立体异构体，其在治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病方面具有用途，例如X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化以及其他与X综合征和心血管疾病有关的疾病。
• Fused heterocyclic derivatives as ppar modulators
  申请人：Conner Eugene Scott

  公开号：US20060205744A1

  公开（公告）日：2006-09-14

  The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S, S(O) 2 and N; (b) U is an aliphatic linker, (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4) A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C 1 -C 6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

  本发明涉及由以下结构式表示的化合物，即式 I： 其中 (a) X 选自单键、O、S、S(O) 2 和 N 所组成的组；(b) U 是脂肪族连接体，(c) Y 选自 C、O、S、NH 和单键组成的组；(d) E 是 C(R3) (R4) A 或 A，其中(i) A 选自羧基、四唑、C 1 -C 6 烷基腈、羧酰胺、磺酰胺和酰基磺酰胺组成的组； (e) B 选自 S、O、C 和 N 组成的组； (f) Z 选自 N 和 C 组成的组；但当 B 为 C 时，Z 为 N。